glp 1 meds canada approves first generic GLP-1 drug in G7 Alberta Blue Cross: GLP-1 Plan

Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)

Nuevo Trifural Plus 10ml Ampolla lipoltica brasilera

One of the first things a developing tumor does is send chemical signals to recruit new vascular supply

At six weeks, ten of twelve patients reported complete symptom resolution, while two achieved 80% improvement